PrimeraDx is dedicated to the emerging field of molecular diagnostics. The company is developing multiplexed, quantitative and cost effective assays using its proprietary STAR technology implemented on the ICEPlex instrument platform. STAR combines quantitative PCR with the ability to multiplex up to 60 targets in a single sample. The Company’s initial products are for infectious disease management. PrimeraDx plans to extend its focus into oncology to support cancer therapy management through diagnostic, prognostic, staging and therapeutic monitoring.
Please email cover letters and CV/resumes to [email protected].